載入中
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
前收盤價
US$3.63
−US$0.21 · -5.47%
盤中時間採用ET。市場資料可能有所延遲。
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
日內區間
目前US$3.63
52週區間
目前US$3.63
盤中時間採用ET。市場資料可能有所延遲。
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
日內區間
目前US$3.63
52週區間
目前US$3.63
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（AUD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 1423.88萬 AUD | 504.38萬 AUD | 384.19萬 AUD | 350.57萬 AUD | 17.04萬 AUD |
| 銷貨成本 | 241.91萬 AUD | 6141.05萬 AUD | 4154.67萬 AUD | 206.18萬 AUD | 206.35萬 AUD |
| 毛利 | 1181.97萬 AUD | −5636.68萬 AUD | −3770.48萬 AUD | 144.39萬 AUD | −189.31萬 AUD |
| 研究與開發 | 7498.17萬 AUD | 6141.05萬 AUD | 4154.67萬 AUD | 2879.34萬 AUD | 3134.16萬 AUD |
| 銷售、一般及管理費用 | 1888.38萬 AUD | 864.45萬 AUD | 885.26萬 AUD | 1408.18萬 AUD | 721.01萬 AUD |
| 營業費用 | 9386.56萬 AUD | 7005.5萬 AUD | 5039.93萬 AUD | 4493.7萬 AUD | 3254.77萬 AUD |
| 利息收入 | 293.94萬 AUD | 525.01萬 AUD | 388.28萬 AUD | 93.9萬 AUD | 22.45萬 AUD |
| 利息支出 | 6.64萬 AUD | — | 3.06萬 AUD | 2.04萬 AUD | 9.24萬 AUD |
| 折舊和攤銷 | 241.91萬 AUD | 248.7萬 AUD | 217.24萬 AUD | 203.01萬 AUD | 206.45萬 AUD |
| 營業利益 | −8204.58萬 AUD | −1.26億 AUD | −8810.42萬 AUD | −7768.85萬 AUD | −3393.76萬 AUD |
| 淨利 | −7757.17萬 AUD | −6143.42萬 AUD | −4271.66萬 AUD | −3989.63萬 AUD | −3221.08萬 AUD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.25
上漲空間 17.08%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
